Akeega (niraparib abiraterone acetate)

Numéro de dossier de l’AMC: 22571
État des négociations:
Négociation envisagée
Indication(s):
Akeega is indicated with prednisone or prednisolone for: The treatment of adult patients with deleterious or suspected deleterious BRCA mutated (germline and/or somatic) metastatic castration resistant prostate cancer (mCRPC), who are asymptomatic/mildly symptomatic, and in whom chemotherapy is not clinically indicated. Patients must have confirmation of BRCA mutation before Akeega treatment is initiated.
Promoteur/fabricant:
Janssen Inc.
Numéro de projet de l’AMC:
PC0326-000
Lettre-contrat de l’APP:
Sans objet
Conclusion du processus de négociation:
Sans objet